<DOC>
	<DOCNO>NCT00087165</DOCNO>
	<brief_summary>RATIONALE : GTI-2040 may stop growth tumor cell block enzymes necessary growth . Drugs use chemotherapy , docetaxel , work different way stop tumor cell divide stop grow die . GTI-2040 may help docetaxel kill tumor cell make sensitive drug . PURPOSE : This phase II trial study well give GTI-2040 together docetaxel prednisone work treat patient prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>GTI-2040 , Docetaxel , Prednisone Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy GTI-2040 , docetaxel , prednisone , term prostate-specific antigen ( PSA ) response rate , patient hormone-refractory prostate cancer . Secondary - Determine objective tumor response patient treat regimen . - Determine median time progression patient treat regimen . - Determine safety tolerability regimen patient . - Determine median duration PSA response patient treat regimen . - Correlate baseline post-treatment level ribonucleotide reductase activity tumor biopsy peripheral blood mononuclear cell tumoral expression c-myc , R2 subunit protein , marker cellular proliferation apoptosis clinical outcome patient treat regimen . OUTLINE : This open-label , multicenter study . Patients receive GTI-2040 IV continuously day 1-14 , docetaxel IV day 3 course 1 day 1 subsequent course , oral prednisone twice daily day 1-21 . Treatment repeat every 21 day 10 course absence disease progression unacceptable toxicity . Patients follow survival . PROJECTED ACCRUAL : A total 18-46 patient accrue study within 3.6-9.5 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Histologically cytologically confirm adenocarcinoma prostate Metastatic carcinoma presumptive prostate origin Bony metastasis AND serum prostatespecific antigen ( PSA ) level &gt; 20 ng/mL Disease progression prior hormonal therapy define rise PSA level At least 2 consecutive rise PSA reference value , measurement take least 7 day apart Prior hormonal therapy must include either medical ( luteinizing hormonereleasing hormone [ LHRH ] agonist ) OR surgical ( orchiectomy ) castration Patients receive prior LHRH agonist must continue restart therapy Castrate level testosterone &lt; 50 ng/dL PSA ≥ 20 ng/mL No known brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy More 3 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 WBC ≥ 3,000/mm^3 Hepatic AST ALT ≤ 1.5 time upper limit normal ( ULN ) Bilirubin normal PTT ≤ 1.25 time upper limit control INR ≤ 1.3 Renal Creatinine ≤ 1.5 time ULN OR Creatinine clearance ≥ 50 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other Fertile patient must use effective contraception No symptomatic peripheral neuropathy ≥ grade 2 No history allergic reaction attribute compound similar chemical biologic composition GTI2040 study agents No concurrent uncontrolled illness No active ongoing infection No psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent prophylactic filgrastim ( GCSF ) epoetin alfa Chemotherapy No prior chemotherapy except monotherapy oral estramustine At least 4 week since prior estramustine recover Endocrine therapy See Disease Characteristics At least 6 week since prior bicalutamide* At least 4 week since prior flutamide , nilutamide , cyproterone* Concurrent steroid allow NOTE : *Patients must evidence disease progression despite cessation antiandrogen therapy Radiotherapy At least 4 week since prior radiotherapy No prior radiotherapy &gt; 25 % bone marrow No prior isotope therapy Surgery See Disease Characteristics Other No concurrent prophylactic antibiotic No concurrent anticoagulants Concurrent lowdose warfarin prophylaxis central line thrombosis allow No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational agent therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>